108P - COMT, APOE, and BDNF gene polymorphisms modulate chemotherapy-induced cognitive impairment in breast cancer survivors

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Complications/Toxicities of treatment
Breast Cancer, Locally Advanced
Translational Research
Presenter Wen Li
Citation Annals of Oncology (2016) 27 (suppl_9): ix30-ix34. 10.1093/annonc/mdw576
Authors W. Li
  • Department Of Oncology, 2nd Hospital of Anhui Medical University, 230601 - Hefei/CN

Abstract

Background

The aim of this study was to investigate whether COMT, APOE and BDNF gene polymorphisms modulate chemotherapy-induced cognitive impairment (CICI) in breast cancer survivors.

Methods

Eighty triple negative breast cancer (TNBC) and 165 non-triple negative breast cancer (NTNBC) matched for age and education were respectively administered with a battery of neuropsychological tests including memory questionnaires before and after chemotherapy. Six single-nucleotide polymorphisms (SNPs) within COMT (rs165599, rs4680, rs737865), APOE(rs429358, rs7412) and BDNF (rs6265) gene were evaluated.

Results

Compared with the memory scores of breast cancer patients before chemotherapy, the score of breast cancer patients after chemotherapy was poorer, exhibited significant difference (t=-5.317, z = -3.372, respectively, p 

Conclusions

The results suggests CICI in TNBC survivors were poorer than NTNBC after chemotherapy, and the COMT rs165599 polymorphism may be a potential genetic marker for increased vulnerability to chemotherapy-induced memory impairment in TNBC survivors.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

National Natural Science Foundation of China

Disclosure

All authors have declared no conflicts of interest.